BACKGROUND: Primary ciliary dyskinesia (PCD) is a rare disease, characterised by chronic airway infection. In cystic fibrosis, FEV1 is insensitive to detect patients with structural damage, and Lung Clearance Index (LCI) was proposed as a better marker of early lung damage. In PCD, the relationship between functional and structural abnormalities has been less studied. We aimed to re-examine this in a cohort of children and adults with mild to moderate PCD. METHODS: Thirty-eight patients with PCD (5.2-25.0 years) and 70 healthy controls (4.4-25.8 years) were recruited to compare LCI, measured by N2 multiple breath washout and FEV1 in a prospective observational trial. In a subset of 30 patients who underwent chest imaging, structural abnormalities were evaluated with cystic fibrosis computed tomography (CFCT) scores. RESULTS: LCI was abnormal in 28 of 38 patients and a moderate correlation was observed between LCI and FEV1 (r=-0.519, p=0.001). Moreover, LCI correlated well with CFCT total score (r=0.800, p<0.001) and also with subscores for airway wall thickening (r=0.809, p<0.001), mucus plugging (r=0.720, p<0.001) and bronchiectasis (r=0.494, p<0.001). Concordance was seen between LCI and CFCT in 25 of 30 (83%) patients, but between FEV1 and CFCT in only 16 of 30 (53%) patients. LCI was more sensitive (90.9%, 95% CI 70.8 to 98.6) to detect patients with structural abnormalities than FEV1 (36.4%, 95% CI 17.2 to 59.3). CONCLUSIONS: We demonstrated that measuring LCI in patients with PCD is of clinical relevance; it was more frequently abnormal than FEV1, correlated well with CFCT and was more sensitive than FEV1 to detect patients with structural abnormalities. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
BACKGROUND:Primary ciliary dyskinesia (PCD) is a rare disease, characterised by chronic airway infection. In cystic fibrosis, FEV1 is insensitive to detect patients with structural damage, and Lung Clearance Index (LCI) was proposed as a better marker of early lung damage. In PCD, the relationship between functional and structural abnormalities has been less studied. We aimed to re-examine this in a cohort of children and adults with mild to moderate PCD. METHODS: Thirty-eight patients with PCD (5.2-25.0 years) and 70 healthy controls (4.4-25.8 years) were recruited to compare LCI, measured by N2 multiple breath washout and FEV1 in a prospective observational trial. In a subset of 30 patients who underwent chest imaging, structural abnormalities were evaluated with cystic fibrosis computed tomography (CFCT) scores. RESULTS:LCI was abnormal in 28 of 38 patients and a moderate correlation was observed between LCI and FEV1 (r=-0.519, p=0.001). Moreover, LCI correlated well with CFCT total score (r=0.800, p<0.001) and also with subscores for airway wall thickening (r=0.809, p<0.001), mucus plugging (r=0.720, p<0.001) and bronchiectasis (r=0.494, p<0.001). Concordance was seen between LCI and CFCT in 25 of 30 (83%) patients, but between FEV1 and CFCT in only 16 of 30 (53%) patients. LCI was more sensitive (90.9%, 95% CI 70.8 to 98.6) to detect patients with structural abnormalities than FEV1 (36.4%, 95% CI 17.2 to 59.3). CONCLUSIONS: We demonstrated that measuring LCI in patients with PCD is of clinical relevance; it was more frequently abnormal than FEV1, correlated well with CFCT and was more sensitive than FEV1 to detect patients with structural abnormalities. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: BreAnna Kinghorn; Sharon McNamara; Alan Genatossio; Erin Sullivan; Molly Siegel; Irma Bauer; Charles Clem; Robin C Johnson; Miriam Davis; Anne Griffiths; William Wheeler; Katherine Johnson; Stephanie D Davis; Margaret W Leigh; Margaret Rosenfeld; Jessica Pittman Journal: Ann Am Thorac Soc Date: 2020-09
Authors: Katharina Schütz; Diana Alecsandru; Bodo Grimbacher; Jamanda Haddock; Annemarie Bruining; Gertjan Driessen; Esther de Vries; Peter M van Hagen; Ieneke Hartmann; Francesco Fraioli; Cinzia Milito; Milica Mitrevski; Isabella Quinti; Goffredo Serra; Peter Kelleher; Michael Loebinger; Jiri Litzman; Vera Postranecka; Vojtech Thon; Judith Babar; Alison M Condliffe; Andrew Exley; Dinakantha Kumararatne; Nick Screaton; Alison Jones; Maria P Bondioni; Vassilios Lougaris; Alessandro Plebani; Annarosa Soresina; Cesare Sirignano; Giuseppe Spadaro; Nermeen Galal; Luis I Gonzalez-Granado; Sabine Dettmer; Robert Stirling; Helen Chapel; Mary Lucas; Smita Patel; Claire-Michele Farber; Isabelle Meyts; Arpan K Banerjee; Scott Hackett; John R Hurst; Klaus Warnatz; Benjamin Gathmann; Ulrich Baumann Journal: J Clin Immunol Date: 2018-12-13 Impact factor: 8.317
Authors: Sharon D Dell; Margaret W Leigh; Jane S Lucas; Thomas W Ferkol; Michael R Knowles; Adrianne Alpern; Laura Behan; Anjana M Morris; Claire Hogg; Audrey DunnGalvin; Alexandra L Quittner Journal: Ann Am Thorac Soc Date: 2016-10
Authors: Laurie J Smith; Noreen West; David Hughes; Helen Marshall; Christopher S Johns; Neil J Stewart; Ho-Fung Chan; Madhwesha Rao; David J Capener; Jody Bray; Guilhem J Collier; Paul J C Hughes; Graham Norquay; Lynne Schofield; Phil Chetcuti; Eduardo Moya; Jim M Wild Journal: Ann Am Thorac Soc Date: 2018-12